RBMS1 and neoplasm: To determine whether RBMS1 ablation-mediated PD-L1 downregulation enhances anti-tumor immunity in vivo, we inoculated 4T1 cells with depleted RBMS1 or control into nude mice (immune deficient) (Figs. S2A and S7).